Title  | Date  | Price |
|---|
Competitor Analysis: EGF-R Agonists and Antagonists
| Oct 2009 |
£270 |
Competitor Analysis: Her2 Receptor Antagonists
| Sep 2009 |
£225 |
Chinese Markets for Colon Cancer Treatment Drugs
| Sep 2009 |
£2,440 |
Chinese Markets for Bladder Cancer Treatment Drugs
| Sep 2009 |
£2,440 |
Chinese Markets for Cervical Cancer Treatment Drugs
| Sep 2009 |
£2,440 |
Chinese Markets for Brain Cancer Treatment Drugs
| Sep 2009 |
£2,440 |
The German Cancer Diagnostics Market
| Sep 2009 |
£2,500 |
The French Cancer Diagnostics Market
| Sep 2009 |
£2,500 |
The Italian Cancer Diagnostics Market
| Sep 2009 |
£2,500 |
The UK Cancer Diagnostics Market
| Sep 2009 |
£2,500 |
Leading Cancer Diagnostics Market Players
Strategic Assessments of Major Suppliers and Emerging Market Entrants
| Sep 2009 |
£1,340 |
Cancer Diagnostic Testing
A Global Market Overview - Facilities, Test Volumes, and Sales Forecasts by Country
| Sep 2009 |
£395 |
The US Cancer Diagnostics Market
| Sep 2009 |
£4,510 |
Cancer Diagnostic Technologies
Assessment of Current and Emerging Technologies, and Their Potential Market Applications
| Sep 2009 |
£1,035 |
Cancer Diagnostic Testing Instrumentation
Operating Characteristics, Features and Selling Prices of Leading Automated and Semiautomated Analyzers
| Sep 2009 |
£305 |
Cancer Diagnostics Market
New Product Development Opportunities, Market Penetration Strategies, Entry Barriers and Risks
| Sep 2009 |
£305 |
Current and Emerging Cancer Diagnostic Tests
Emerging Assays and Companies Developing New Technologies and Products
| Sep 2009 |
£1,740 |
The Spanish Cancer Diagnostics Market
| Sep 2009 |
£2,500 |
The Japanese Cancer Diagnostics Market
| Sep 2009 |
£3,475 |
Competitive Outlook on Lung Cancer Drug Development
The Missing Handbook to New Product Planning and Portfolio Planning
| Aug 2009 |
£2,240 |
CHK and KSP/Eg5 Inhibitors
Competitor Analysis
| Aug 2009 |
£160 |
Cancer Drug Discoveries: Colorectal Cancer
What the future holds
| Jul 2009 |
£1,295 |
Bcr-Abl Kinase Inhibitors
Competitor Analysis
| Jul 2009 |
£180 |
IGF-1R Antagonists
Competitor Analysis
| Jul 2009 |
£225 |
HDAC Inhibitors
Competitor Analysis
| Jul 2009 |
£360 |
Immunotoxins
Competitor Analysis
| Jul 2009 |
£135 |
PI3K-Akt-mTOR Pathway Inhibitors
Competitor Analysis
| Jul 2009 |
£450 |
Immunocytokines
Competitor Analysis
| Jun 2009 |
£135 |
MEK Inhibitors
Competitor Analysis
| Jun 2009 |
£135 |
Antibody-Drug Conjugates (ADC)
Competitor Analysis
| Jun 2009 |
£225 |
Aurora Kinase Inhibitors
Competitor Analysis
| Jun 2009 |
£160 |
Therapeutic Peptides in Oncology
Favorable Conditions But Where to Commercialize?
| May 2009 |
£3,235 |
Novel Mitotic Kinase Inhibitors
Competitor Analysis
| May 2009 |
£315 |
Ras-Raf-MEK-ERK Inhibitors
Competitor Analysis
| May 2009 |
£315 |
Raf Inhibitors
Competitor Analysis
| May 2009 |
£180 |
World Market for Cancer Therapeutics and Biotherapeutics, 3rd. Edition, The
| May 2009 |
£2,435 |
PARP Inhibitors
Competitor Analysis
| Apr 2009 |
£90 |
Prostate Cancer Therapeutics
| Apr 2009 |
£2,410 |
Leukemia
A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking
| Apr 2009 |
£1,780 |
Hypoxia-Inducible Factor (HIF)
Competitor Analysis
| Apr 2009 |
£90 |
Multiple Myeloma Therapeutics
| Apr 2009 |
£2,410 |
Looking at the Cancer Therapy Market
| Apr 2009 |
£425 |
CD3 Antagonists
Competitor Analysis
| Mar 2009 |
£180 |
Cancer Therapies
| Feb 2009 |
£2,410 |
Global Dialysis Market Report: 2009 Edition
| Feb 2009 |
£515 |
Chinese Markets for Lung Cancer Treatment Drugs
| Feb 2009 |
£2,440 |
Chinese Markets for Prostate Cancer Treatment Drugs
| Feb 2009 |
£2,440 |
Chinese Markets for Breast Cancer Treatment Drugs
| Feb 2009 |
£2,440 |
Apoptosis in Oncology: Drug Pipeline Update 2009
| Jan 2009 |
£1,370 |
Melanoma Drug Pipeline Update 2009
| Jan 2009 |
£1,370 |
Renal Cancer Drug Pipeline Update 2009
| Jan 2009 |
£1,370 |
Leukemia Drug Pipeline Update 2009
| Jan 2009 |
£1,370 |
Bladder Cancer Drug Pipeline Update 2009
| Jan 2009 |
£915 |
Protein Kinase C (PKC) Inhibitors
Competitor Analysis
| Jan 2009 |
£180 |
Hematological Cancers Drug Pipeline Update 2009
| Jan 2009 |
£1,825 |
Antibodies in Oncology: Drug Pipeline Update 2009
| Jan 2009 |
£1,370 |
Pancreatic Cancer Drug Pipeline Update 2009
| Jan 2009 |
£1,370 |
Prostate Cancer: Drug Pipeline Update 2009
| Jan 2009 |
£1,370 |
Brain Cancer Drug Pipeline Update 2009
| Jan 2009 |
£1,370 |
Immunotherapy in Oncology: Drug Pipeline Update 2009
| Jan 2009 |
£1,825 |
Breast Cancer Drug Pipeline Update 2009
| Jan 2009 |
£1,370 |
Analytical Tool - Melanoma
| Jan 2009 |
£2,835 |
Pipeline Insight: Cancer Overview
Gastrointestinal, Skin, Sarcomas
| Jan 2009 |
£6,950 |
Lung Cancer Drug Pipeline Update 2009
| Jan 2009 |
£1,370 |
Ovarian Cancer Drug Pipeline Update 2009
| Jan 2009 |
£1,370 |
Lymphoma Drug Pipeline Update 2009
| Jan 2009 |
£1,370 |
Cancer Market Trends 2008 - 2012
| Jan 2009 |
£1,100 |
Analytical Tool - Breast Cancer
| Jan 2009 |
£2,835 |
Colorectal Cancer Drug Pipeline Update 2009
| Jan 2009 |
£1,370 |
Analytical Tool - Prostate Cancer
A Therapeutic & Competitive Insight
| Jan 2009 |
£2,835 |
Analytical Tool - Apoptosis in Oncology
| Jan 2009 |
£2,835 |
Liver Cancer Drug Pipeline Update 2009
| Jan 2009 |
£915 |
Stakeholder Opinions: Cancer Cachexia - Higher profile needed to unlock market potential of neglected syndrome
| Jan 2009 |
£2,315 |
Protein Kinase Inhibitors in Oncology: Drug Pipeline Update 2009
| Jan 2009 |
£1,370 |
Angiogenesis in Oncology: Drug Pipeline Update 2009
| Jan 2009 |
£1,370 |
CD20 Antibodies
Competitor Analysis
| Jan 2009 |
£180 |
China Anti-Cancer Drug Market Report
The Chinese Hospital Cancer Drug Utilization
| Dec 2008 |
£4,950 |
U.S. Cancer Molecular Diagnostics Markets
| Dec 2008 |
£3,660 |
Global Radiation Therapy Market: 2008 Edition
| Nov 2008 |
£545 |
Stakeholder Insight: Chronic Leukemias
Is there room left for improvement?
| Nov 2008 |
£8,070 |
Cancer Vaccines
Market Forecasts, New Developments and Pipeline Analysis
| Nov 2008 |
£2,435 |
Pipeline Insight: Molecular Targeted Cancer Therapies
More pipeline activity, less product differentiation
| Nov 2008 |
£8,070 |
Who's Developing What in Drug Delivery?
| Oct 2008 |
£595 |
c-MET/HGF Inhibitors
Competitor Analysis
| Oct 2008 |
£225 |
European Cancer IVD Market
| Oct 2008 |
£3,965 |
Currently Druggable in Prostate Cancer
A Drug Target Competitive Analysis
| Sep 2008 |
£1,780 |
Cancer Drug Resistance 2008
| Sep 2008 |
£1,675 |
Global Cancer Treatment Forecast to 2012
| Aug 2008 |
£975 |
Currently Druggable in Breast Cancer
A Drug Target Competitive Analysis
| Aug 2008 |
£1,780 |
Cytology and HPV Testing World Markets
| Jul 2008 |
£2,105 |
Cancer Biomarkers
Adoption Is Driving Growth
| Jul 2008 |
£2,285 |
Cancer Personalized Medicine 2008
| Jul 2008 |
£2,425 |
European Lung Cancer Therapeutics Markets
| Jun 2008 |
£3,965 |
Integrin Antagonists
Competitor Analysis
| Jun 2008 |
£225 |
Emerging Trends in Cancer Therapies (Small Molecule Drugs and Biologicals) (Technical Insights)
| Jun 2008 |
£3,965 |
Cancer Antibodies
Competitive Positioning for Success
| Jun 2008 |
£1,780 |
Cancer Therapeutics Markets
| May 2008 |
£2,105 |
Cancer Vaccines
Aim and Shoot
| May 2008 |
£1,780 |
Heat shock protein 90 (Hsp90) Inhibitors
Competitor Analysis
| May 2008 |
£115 |
previous
